FibroBiologics, Inc. Common Stock

FBLGNASDAQHealthcare

$1.38+0.05(+3.76%)

$1.0352-Week Range$30.60

Mkt Cap$3M

P/E—

EPS—

Div Yield—

Volume797K

Monitoring…

FibroBiologics, Inc. Common Stock (FBLG) Overview

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

FibroBiologics, Inc. Common Stock operates in the Healthcare sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for FBLG.

Healthcare Earnings History Insider Trading Stock Screener

Pulse Score

C56.0/100

Value

11/20

Growth

12.5/20

Health

11/20

Momentum

9.5/20

Sentiment

12/20

AI Quick Take

AI analysis is being generated. Visit the AI Intel tab for detailed analysis.

Price Trend (30D)

52W Low: $1.0352W High: $30.60

Analyst Consensus

Buy 7Hold 2Sell 0

Target: $9.00(+552.2%)

Earnings Track Record

May 26

Miss +0.0%

Feb 26

Miss -733.3%

Oct 25

Miss -30.0%

Jul 25

Miss -9.1%

Latest Signals

Khoja bought 30K shares

Mar 4

O'HEERON bought 16K shares

Mar 4

How Much Would You Have if You Had Invested $2,000...

17h ago

Tech Corner: AAPL Builds Up Tech Ecosystem

18h ago

Key Statistics

Market Cap

$2.9M

P/E Ratio

-0.5

EPS

$-0.98

Volume

797K

Avg Volume

—

Open

$1.31

Prev. Close

$1.33

Day Range

$1.19 - $1.47

50-Day Avg

$5.65

200-Day Avg

$8.54

52W High

$30.60

52W Low

$1.03

$1.0352-Week Range$30.60

Price Performance

+3.8%

-63.5%

-83.5%

-71.7%

-87.4%

YTD

-71.3%

-92.1%

-99.8%

Growth Rates (YoY)

Revenue

0.0%

Net Income

-67.1%

EPS

-23.5%

Free Cash Flow

-37.8%

FY 2025 vs FY 2024

Shares & Float

Outstanding

2.1M

Float

1.6M

Free Float

76.5%

Earnings Track Record

—

Aug 24

+0.0%

—

Nov 24

+0.0%

✓

Mar 25

+5.7%

✓

Mar 25

+10.0%

✗

Jul 25

-9.1%

✗

Oct 25

-30.0%

✗

Feb 26

-733.3%

—

May 26

Beat estimates 2 of 7 quarters (29%)

About

CEO

Peter O'Heeron

Sector

Healthcare

Industry

Biotechnology

Website

Recent SEC Filings

2026-04-03

2026-04-02

2026-03-27

2026-03-06

2026-03-05

Latest FibroBiologics, Inc. Common Stock News

How Much Would You Have if You Had Invested $2,000 In Apple When It Went Public?

The Motley Fool·17h ago

Tech Corner: AAPL Builds Up Tech Ecosystem

Schwab Network·18h ago

Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years?

The Motley Fool·21h ago

The Fed Held Rates Again: Why Long-Term Investors May Not Need to Do Anything

The Motley Fool·21h ago

Apple at 50: The iPhone maker 'blew a 5-year lead' on AI, but former insiders say it can still win

CNBC·23h ago

2,057 Shares in Apple Inc. $AAPL Acquired by Demming Financial Services Corp ADV

Defense World·1d ago

Apple Inc. $AAPL Stake Increased by Stableford Capital II LLC

Defense World·1d ago

Signal Advisors Wealth LLC Acquires 50,263 Shares of Apple Inc. $AAPL

Defense World·1d ago

Financial Summary

ExchangeNASDAQ Capital Market

CIK0001958777

ISINUS31573L2043

CUSIP31573L204

Market Cap$2.9M

Beta1.105

Employees13

Phone281 651 5150

Address455 East Medical Center Boulevard, Houston

CountryUS

IPO Date2024-02-01

AI Summary Hub

StoxPulse AI results for FBLG: Pulse Score 56/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.

FibroBiologics, Inc. Common Stock